BioCentury | Jun 13, 2011
Finance

Ambit's gambit

...the company will allocate some of the money to two Phase I compounds: cancer candidate AC480...
BioCentury | Jan 3, 2011
Clinical News

AC430: Phase I started

...oral AC430 in healthy volunteers. Ambit Biosciences Corp. , San Diego, Calif. Product: AC430 ( BMS-599626...
BioCentury | Jan 3, 2011
Clinical News

AC480: Phase I started

...Ambit began an open-label, dose-escalation Phase I trial to evaluate IV AC480 given on the first...
...days of a 21-day cycle with or without Taxotere docetaxel in 100 patients. Ambit licensed AC480...
...Corp. , San Diego, Calif. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: AC480 ( BMS-599626...
Items per page:
1 - 3 of 3